Natus Medical: Olympic Medical Facility a 'Sound Strategic Fit'
-
Font Size:
-
Print
- TweetThis
In addition, they spent time checking out the CFM and CoolCap devices. Firm believes both devices complement each other not only in the diagnosis and treatment of HIE, but also with respect to manufacturing, as both devices are housed and comprised of similar technology. They expect this latter point to provide significant profitability out of the CoolCap device.
At Roth's recent growth stock conference, Natus' management discussed its long-term corporate goals of achieving a revenue run rate toward the $250 million level by 4Q08 and to grow EPS by close to 50% annually. Firm believes management's track record over the past few years has demonstrated an ability to execute this type of combined organic and acquisition-based strategy, while driving toward enhanced profitability.
Firm reiterates Buy and raises price target to $22 from $20.
Notablecalls: This note might move this baby.
BABY 1-yr chart

Related Articles
|























